Clarivate (CLVT)
NYSE:CLVT
Top Page
Clarivate
(NYSE:CLVT)
Select Model
Select Model
Rating:54Neutral
Price Target:
$2.50
▲(8.70% Upside)
Action:ReiteratedDate:02/25/26
The score is driven primarily by strengthening financial execution and cash generation, reinforced by constructive 2026 guidance (margin expansion and higher EPS/FCF). These positives are tempered by a weak longer-term price trend and valuation limitations from ongoing unprofitability, alongside leverage and modest/declining revenue dynamics.
Positive Factors
Cash Generation
Material improvement in cash conversion provides durable optionality: stronger FCF supports sustained deleveraging, targeted buybacks, and reinvestment in product development without relying on equity markets. This underpins balance-sheet repair and strategic flexibility over months.
Negative Factors
Flat / Declining Revenue
Strategic disposals and a largely flat organic top line constrain operating leverage. With transactional wind‑downs and modest recurring growth, revenue headwinds limit the pace of margin-driven earnings gains and slow debt paydown absent stronger organic growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Material improvement in cash conversion provides durable optionality: stronger FCF supports sustained deleveraging, targeted buybacks, and reinvestment in product development without relying on equity markets. This underpins balance-sheet repair and strategic flexibility over months.
Read all positive factors
Clarivate (CLVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.47B
Dividend YieldN/A
Average Volume (3M)5.54M
Price to Earnings (P/E)176.2
Beta (1Y)0.93
Revenue Growth-2.96%
EPS Growth71.30%
CountryUS
Employees12,000
SectorTechnology
Sector Strength88
IndustryInformation Technology Services
Share Statistics
EPS (TTM)0.20
Shares Outstanding640,698,600
10 Day Avg. Volume6,775,614
30 Day Avg. Volume5,535,747
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.46
Price to Sales (P/S)0.92
P/FCF Ratio6.16
Enterprise Value/Market Cap3.76
Enterprise Value/Revenue2.26
Enterprise Value/Gross Profit3.42
Enterprise Value/Ebitda6.69
Forecast
1Y Price Target
$3.46Price Target Upside50.43% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)0.73
Revenue Forecast (FY)$2.36B
Clarivate Business Overview & Revenue Model
Company Description
Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and ser...
How the Company Makes Money
Clarivate primarily makes money by selling access to its proprietary datasets, analytics, and workflow software through recurring subscriptions (often sold as annual contracts) to institutions and enterprises. A major revenue stream is recurring s...
Clarivate Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful operational progress and clear positive momentum: the company hit its full-year guidance, improved recurring revenue mix and ACV trends, delivered >$1 billion adjusted EBITDA and $365 million of free cash flow, and outlined optimistic 2026 guidance (2-3% ACV growth, ~10% FCF growth). Management emphasized AI-driven product innovation and adoption (multiple product launches and user adoption metrics) and initiated a strategic review of the portfolio with a potential LS&H sale to accelerate value creation. Offsetting these positives are near-term top-line pressures from disposals and transactional wind-downs (expected revenue decline ~ $100M midpoint in 2026), modest organic revenue growth (flat overall), higher near-term operating expense/investment, and a multi-year turnaround required in parts of IP. On balance, the positives (cash generation, margin expansion potential, AI/product traction, and concrete capital-deployment actions) outweigh the negatives, supporting an optimistic outlook.Positive Updates
Achieved Full-Year Guidance and Improved Operational Momentum
Clarivate delivered on its initial full-year 2025 financial guide for the first time since 2019, citing improved execution across sales, product innovation and cost discipline that laid a foundation for 2026.
Negative Updates
Flat to Slightly Negative Organic Revenue
While subscription/ACV trends improved, total organic revenue was essentially flat for the full year and declined about 1% in Q4 as subscription growth (~1% organic subscription revenue growth) was offset by declines in transactional revenue.
Read all updates
Q4-2025 Updates
Positive
Negative
Achieved Full-Year Guidance and Improved Operational Momentum
Clarivate delivered on its initial full-year 2025 financial guide for the first time since 2019, citing improved execution across sales, product innovation and cost discipline that laid a foundation for 2026.
Read all positive updates
Company Guidance
For 2026 Clarivate guided to 2–3% organic ACV growth (a ~0.75 ppt midpoint improvement), 1–2% recurring organic revenue growth (midpoint ~1.5%), total revenue at the midpoint of roughly $2.36B (about a $100M–$130M decline driven by strategic disposals, noting the guidance assumes ownership of LS&H for the full year), an improved organic recurring revenue mix of 88–90%, modest adjusted EBITDA growth with margin expansion of ~200 bps to nearly 43% at the midpoint (Q4 run‑rate was just over 41%), diluted adjusted EPS of about $0.75 (≈9% increase at the midpoint), and free cash flow of ~ $400M (≈$35M or ~10% growth vs. 2025’s $365M); management also flagged drivers and cushions including an expected FX benefit (~$10M top line / $5M bottom line), ~$20M cash interest savings, a ~$20M working capital use versus last year’s source, ~$15M capex improvement, and timing effects that should produce a slight Q1 pullback with recurring organic growth essentially flat in Q1.Clarivate Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
52
Neutral
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.46B | 2.56B | 2.63B | 2.66B | 1.88B |
| Gross Profit | 1.62B | 1.69B | 1.72B | 1.71B | 1.25B |
| EBITDA | 828.70M | 456.60M | -10.50M | -3.01B | 532.15M |
| Net Income | -201.10M | -636.70M | -911.20M | -3.96B | -270.50M |
Balance Sheet | |||||
| Total Assets | 11.07B | 11.49B | 12.71B | 13.94B | 20.18B |
| Cash, Cash Equivalents and Short-Term Investments | 329.20M | 295.20M | 370.70M | 348.80M | 587.61M |
| Total Debt | 4.48B | 4.59B | 4.81B | 5.10B | 5.61B |
| Total Liabilities | 6.23B | 6.35B | 6.71B | 7.13B | 8.26B |
| Stockholders Equity | 4.84B | 5.14B | 5.99B | 6.81B | 11.93B |
Cash Flow | |||||
| Free Cash Flow | 365.30M | 357.50M | 501.70M | 306.40M | 205.30M |
| Operating Cash Flow | 628.50M | 646.60M | 744.20M | 509.30M | 323.80M |
| Investing Cash Flow | -263.20M | -236.70M | -237.40M | 57.30M | -4.04B |
| Financing Cash Flow | -343.10M | -470.10M | -496.50M | -759.20M | 4.03B |
Clarivate Technical Analysis
Negative
2.30
Price Trends
2.35
Negative
2.88
Negative
3.45
Negative
Market Momentum
>-0.01
Positive
41.37
Neutral
34.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLVT, the sentiment is Negative. The current price of 2.3 is below the 20-day moving average (MA) of 2.49, below the 50-day MA of 2.35, and below the 200-day MA of 3.45, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.37 is Neutral, neither overbought nor oversold. The STOCH value of 34.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLVT.
Clarivate Risk Analysis
Clarivate disclosed 44 risk factors in its most recent earnings report. Clarivate reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clarivate Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $6.27B | 14.72 | 21.81% | 1.41% | 7.40% | -14.45% | |
72 Outperform | $4.78B | 27.23 | 25.50% | ― | 14.43% | 29.86% | |
68 Neutral | $29.17B | 17.90 | 14.84% | 1.46% | 7.44% | -4.57% | |
68 Neutral | $7.04B | 30.32 | 10.27% | ― | 14.26% | -15.49% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | $10.53B | 24.91 | 74.65% | ― | 5.24% | -16.05% | |
54 Neutral | $1.47B | 176.21 | -4.07% | ― | -2.96% | 71.30% |
* Technology Sector Average
CLVT
Clarivate
2.30
-0.90
-28.13%
CTSH
Cognizant
61.00
-7.28
-10.66%
EPAM
Epam Systems
129.99
-16.30
-11.14%
EXLS
Exlservice Holdings
30.55
-13.47
-30.60%
IT
Gartner
149.40
-242.63
-61.89%
G
Genpact
36.93
-9.02
-19.62%
Clarivate Corporate Events
Business Operations and StrategyExecutive/Board Changes
Clarivate Updates Executive Severance Plan and Equity Vesting
Neutral
Mar 26, 2026
On March 23, 2026, Clarivate’s board approved an Amended and Restated Executive Severance Plan, updating the executive protections originally put in place on June 30, 2021. The plan continues to cover members of the Executive Leadership Team...
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Clarivate Advances Subscription Model, Explores Life Sciences Divestiture
Positive
Feb 24, 2026
On February 24, 2026, Clarivate reported fourth-quarter and full-year 2025 results showing lower reported revenue due to divestitures but improving quality of earnings, with organic ACV up 1.8%, recurring organic revenue growing and the mix of rec...
Business Operations and StrategyRegulatory Filings and Compliance
Clarivate Shares AI-Focused Intelligence Webinar With Investors
Neutral
Feb 3, 2026
On February 3, 2026, Clarivate made available on the investor relations section of its website a video webinar titled “Intelligence Amplified in the Age of AI,” along with related presentation materials, as part of its communications t...
Business Operations and StrategyStock Buyback
Clarivate redeems notes, advances capital allocation strategy
Positive
Feb 2, 2026
On January 30, 2026, Clarivate’s subsidiary Camelot Finance S.A. fully redeemed the remaining $100 million principal amount of its 4.50% senior secured notes due 2026 at par plus accrued interest, funded with cash on hand, and subsequently s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.